Effectiveness of activated vitamin D3 on improving prognosis of osteosarcoma patients

Oncology Reports

Volumn 8, Issue 2, 2001, Pages 321-324

  Nozaki, Takako ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

Author keywords

Activated vitamin D3; Ostcosarcoma; Prognosis

Indexed keywords

ANTINEOPLASTIC AGENT; CALCIFEDIOL; CISPLATIN; DOXORUBICIN;

ADOLESCENT; ADULT; ARTICLE; BONE TUMOR; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; MALE; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; OSTEOSARCOMA; PROGNOSIS; SURVIVAL RATE; TIME;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; CALCIFEDIOL; CHILD; CISPLATIN; COMBINED MODALITY THERAPY; DOXORUBICIN; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; OSTEOSARCOMA; PROGNOSIS; SURVIVAL RATE; TIME FACTORS;

EID: 0035286365     PISSN: 1021335X     EISSN: None     Source Type: Journal    
DOI: 10.3892/or.8.2.321     Document Type: Article

References (2)

1. Hara K: The experimental study of the anti-tumor effect of activated vitamin D3 on Dunn murinc ostcosarcoma. J Kyoto Pref Univ Med 97: 1255-1268, 1988.
2. Enneking WF: Staging musculoskcletal tumors. In: Musculoskeletal Tumor Surgery. Enneking WF (ed). Churchill Livingstone, New York, pp69-88, 1983.